Seemal F. Awan

Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults

Richard L Wu, Katherine V. Houser, Martin R. Gaudinski, Alicia T. Widge et autres

us (code pays fourni par la source)

Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS

Seemal F. Awan, Amarendra Pegu, Larisa Strom, Cristina Carter et autres

BACKGROUNDBroadly neutralizing monoclonal antibodies (bNAbs) represent a promising strategy for HIV-1 immunoprophylaxis and treatment. 10E8VLS and VRC07-523LS are bNAbs that target the highly conserved membrane-proximal external region (MPER) and the CD4-binding site of the HIV-1 viral envelope glycoprotein, respectively.METHODSIn this phase 1, …

us (code pays fourni par la source)

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults

Alicia T. Widge, Amelia R. Hofstetter, Katherine V. Houser, Seemal F. Awan et autres

Influenza vaccines could be improved by platforms inducing cross-reactive immunity. Immunodominance of the influenza hemagglutinin (HA) head in currently licensed vaccines impedes induction of cross-reactive neutralizing stem-directed antibodies. A vaccine without the variable HA head domain has the potential to focus the …

us (code pays fourni par la source)

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria

Richard L Wu, Azza H. Idris, Nina M. Berkowitz, Myra Happe et autres

BACKGROUND: New approaches for the prevention and elimination of malaria, a leading cause of illness and death among infants and young children globally, are needed. METHODS: (3D7 strain). RESULTS: was 164.8±31.1 in the participants who had received 5 mg per kilogram intravenously …

us (code pays fourni par la source)

Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection

Seemal F. Awan, Myra Happe, Amelia R. Hofstetter, Lúcio Gama

PURPOSE OF REVIEW: Anti-HIV-1 broadly neutralizing antibodies (bNAbs) are promising agents in the fight against the AIDS epidemic. Multiple bNAbs have been already evaluated in clinical trials with encouraging results. This review discusses the use of bNAbs for the prevention and treatment …

us (code pays fourni par la source)

CRISPR screening reveals mechanisms of IgE + B‐cell constraint

Seemal F. Awan, Tamara Haque, Stephanie Kubala

-

us (code pays fourni par la source)

Acute increases in total serum tryptase unassociated with hemodynamic instability in diffuse cutaneous mastocytosis

Seemal F. Awan, Larry Schwartz, Irina Marić, Dean D. Metcalfe et autres

us (code pays fourni par la source)

Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

Joseph P. Casazza, Evan M. Cale, Sandeep Narpala, Galina V. Yamshchikov et autres

us (code pays fourni par la source)

Overlay Between Th1 and Th2 pathways in Patients with Common Variable Immunodeficiency and Allergic disease

Seemal F. Awan, Pavan Nataraj, Martin Maldonado-Puebla, Pooja Dave et autres

us (code pays fourni par la source)

Asthma is associated with increased risk of intubation but not hospitalization or death in coronavirus disease 2019

Jamie A. Rosenthal, Seemal F. Awan, Jonathan Fintzi, Anjeni Keswani et autres

us (code pays fourni par la source)

Sweet Care: Improving Diabetes Outpatient Quality Measurements with Implementation of EMR Based “Macros”

Seemal F. Awan, James Mitchell, Jeffrey Lankowsky, Daniel Beatty et autres

An Orphan Disease – Idiopathic Retroperitoneal Fibrosis

Leah Breen, Seemal F. Awan